Long-term use of clomiphene in male macroprolactinomas with persistent hypogonadism.
| Title: | Long-term use of clomiphene in male macroprolactinomas with persistent hypogonadism. |
|---|---|
| Authors: | Stumpf, Matheo A. M., Galliano, Stefano A., Bueno, Cristina B. F., Glezer, Andrea |
| Source: | Endocrine (1355008X); Jul2024, Vol. 85 Issue 1, p152-157, 6p |
| Abstract: | Background: Men with macroprolactinoma can present persistent hypogonadism despite normoprolactinemia achieved with clinical and/or neurosurgical treatment. Usually, testosterone replacement therapy is indicated. Nevertheless, although off-label, clomiphene citrate (CC), a selective estrogen receptor modulator, has also been used, mainly when fertility is an issue. The aim of this study is to evaluate the effectiveness of CC in recovering the gonadal axis in men with macroprolactinoma, with or without hyperprolactinemia, and evaluate its safety as a long-term therapy. Methods: This is a retrospective study including 10 men with macroprolactinoma on cabergoline treatment and persistent hypogonadism. All patients received initially 50 mg/d of CC. Results: The median age at diagnosis of prolactinomas was 34 (range, 26–60) years old. All patients were treated with cabergoline at a median maximum dose of 2 (1–7) mg/week, with a median time of treatment of 8.5 (2–15) years. Prolactin was still above the normal range when CC was introduced only in two patients. The mean duration of CC therapy was 3.2 (±2.8) years. Prolactin levels maintained stable (p = 0.252) and testosterone increased (p = 0.027) significantly on CC therapy. Tumor size remained stable. Eight patients (80%) maintained testosterone above 300 ng/dL and were classified as responders. Three responders succeeded in using a lower dose of CC and one of them completed withdrawal CC and maintained eugonadism. There were no side effects or safety concerns reported. Conclusion: CC should be seen as a safe treatment option for men with macroprolactinoma and persistent hypogonadism. [ABSTRACT FROM AUTHOR] |
| Copyright of Endocrine (1355008X) is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Database: | Complementary Index |
| FullText | Text: Availability: 0 CustomLinks: – Url: https://resolver.ebsco.com/c/xy5jbn/result?sid=EBSCO:edb&genre=article&issn=1355008X&ISBN=&volume=85&issue=1&date=20240701&spage=152&pages=152-157&title=Endocrine (1355008X)&atitle=Long-term%20use%20of%20clomiphene%20in%20male%20macroprolactinomas%20with%20persistent%20hypogonadism.&aulast=Stumpf%2C%20Matheo%20A.%20M.&id=DOI:10.1007/s12020-024-03817-0 Name: Full Text Finder (for New FTF UI) (s8985755) Category: fullText Text: Find It @ SCU Libraries MouseOverText: Find It @ SCU Libraries |
|---|---|
| Header | DbId: edb DbLabel: Complementary Index An: 178415711 RelevancyScore: 1023 AccessLevel: 6 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 1022.79699707031 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Long-term use of clomiphene in male macroprolactinomas with persistent hypogonadism. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AR" term="%22Stumpf%2C+Matheo+A%2E+M%2E%22">Stumpf, Matheo A. M.</searchLink><br /><searchLink fieldCode="AR" term="%22Galliano%2C+Stefano+A%2E%22">Galliano, Stefano A.</searchLink><br /><searchLink fieldCode="AR" term="%22Bueno%2C+Cristina+B%2E+F%2E%22">Bueno, Cristina B. F.</searchLink><br /><searchLink fieldCode="AR" term="%22Glezer%2C+Andrea%22">Glezer, Andrea</searchLink> – Name: TitleSource Label: Source Group: Src Data: Endocrine (1355008X); Jul2024, Vol. 85 Issue 1, p152-157, 6p – Name: Abstract Label: Abstract Group: Ab Data: Background: Men with macroprolactinoma can present persistent hypogonadism despite normoprolactinemia achieved with clinical and/or neurosurgical treatment. Usually, testosterone replacement therapy is indicated. Nevertheless, although off-label, clomiphene citrate (CC), a selective estrogen receptor modulator, has also been used, mainly when fertility is an issue. The aim of this study is to evaluate the effectiveness of CC in recovering the gonadal axis in men with macroprolactinoma, with or without hyperprolactinemia, and evaluate its safety as a long-term therapy. Methods: This is a retrospective study including 10 men with macroprolactinoma on cabergoline treatment and persistent hypogonadism. All patients received initially 50 mg/d of CC. Results: The median age at diagnosis of prolactinomas was 34 (range, 26–60) years old. All patients were treated with cabergoline at a median maximum dose of 2 (1–7) mg/week, with a median time of treatment of 8.5 (2–15) years. Prolactin was still above the normal range when CC was introduced only in two patients. The mean duration of CC therapy was 3.2 (±2.8) years. Prolactin levels maintained stable (p = 0.252) and testosterone increased (p = 0.027) significantly on CC therapy. Tumor size remained stable. Eight patients (80%) maintained testosterone above 300 ng/dL and were classified as responders. Three responders succeeded in using a lower dose of CC and one of them completed withdrawal CC and maintained eugonadism. There were no side effects or safety concerns reported. Conclusion: CC should be seen as a safe treatment option for men with macroprolactinoma and persistent hypogonadism. [ABSTRACT FROM AUTHOR] – Name: Abstract Label: Group: Ab Data: <i>Copyright of Endocrine (1355008X) is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.) |
| PLink | https://login.libproxy.scu.edu/login?url=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edb&AN=178415711 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1007/s12020-024-03817-0 Languages: – Code: eng Text: English PhysicalDescription: Pagination: PageCount: 6 StartPage: 152 Titles: – TitleFull: Long-term use of clomiphene in male macroprolactinomas with persistent hypogonadism. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Stumpf, Matheo A. M. – PersonEntity: Name: NameFull: Galliano, Stefano A. – PersonEntity: Name: NameFull: Bueno, Cristina B. F. – PersonEntity: Name: NameFull: Glezer, Andrea IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 07 Text: Jul2024 Type: published Y: 2024 Identifiers: – Type: issn-print Value: 1355008X Numbering: – Type: volume Value: 85 – Type: issue Value: 1 Titles: – TitleFull: Endocrine (1355008X) Type: main |
| ResultId | 1 |